HYBRID EVENT: You can participate in person at Orlando, Florida, USA or Virtually from your home or work.

12th Edition of International Conference on Neurology and Brain Disorders

October 20-22, 2025

October 20 -22, 2025 | Orlando, Florida, USA
INBC 2025

Alzheimer's disease counteracted by intravenous antioxidants biosupplements administration

Speaker at Neurology Conferences - Juan Moreira
Centro Neurointegrativo Gnosis, Puerto Rico
Title : Alzheimer's disease counteracted by intravenous antioxidants biosupplements administration

Abstract:

Background: Alzheimer’s disease is the most common form of dementia, accounting for 60% to 70% of cases. (1) Current research indicates that oxidative stress is the principal cause of pathology linked to Alzheimer’s disease. (2-6) Neuronal degeneration in this disorder is considered to be caused by the secondary effects of an increase in oxidation and lower mitochondrial bioenergetics with the lack of energy ending in neuronal death. (2-6)

A reduction in ATP levels is caused by mitochondrial malfunctions that are characterized by decreased electron transport rates in complex I, III and IV of the mitochondrial respiration, increased oxidative stress – reactive oxidative species, decrease in glucose utilization associated to decrease activity and expression of Pyruvate Dehydrogenase Complex (PDH), elevation in glycolysis and loss in metabolic capabilities are early AD pathophysiological findings (2-6)

Rationality: Infusion therapy of intravenous and/or intraspinal cranio-cervical injections of antioxidant biosupplements may serve to counteract the oxidation and inflammation that occurs in Alzheimer's disease by increasing the redox potential inside the mitochondria, which facilitate the production of neurotransmitters and reverse the loss of brain energy production at the chemical level, halting the cognitive deficit progression.

Methodology: In the first month, fifty (50) patients received two initial infusion treatments, which was then followed by a monthly infusion per year. Intravenous biosupplements (NAD, Alpha Lipoic Acid, Vitamin C, Glutathione,) were administered. MOCA and ADAS- cog were measured at baseline and after one year receiving treatment.

Results: Twenty-seven (27) of the fifty patients showed no signs of deterioration, eighteen (18) showed mild improvement at the end of the year on MOCA and ADAS-cog. Five (5) patients showed mild deterioration. No side effects were observed.

Conclusion: Clinical symptoms of Alzheimer’s disease can be medically controlled with an appropriate intravenous bionutritional antioxidant combination as a treatment by improving the energy production of the brain. A clinical trial with a larger population should be considered.

Biography:

Dr. Juan Moreira is a board-certified neurologist with dual fellowship training in vascular neurology and neuroimaging. With over 25 years of experience, he has consistently demonstrated a commitment to delivering top-quality healthcare across hospital, emergency room, and ambulatory care settings. From 1995 to 2022, he successfully operated a private neurology practice, earning a reputation for clinical excellence and patient-centered care. His expertise includes advanced treatments such as Botox therapy, Transcranial Magnetic Stimulation (TMS), and Laser Photobiomodulation. In addition to his clinical practice, he has a growing interest in clinical research and seeks to contribute to an institution dedicated to innovation, academic excellence, and cutting-edge neurological care.

Watsapp